Abstract:Objective To investigate the clinical characteristics,associated risk factors and therapeutic effectiveness of chronic graft-versus-host disease(cGVHD)after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods The clinical data of cGVHD were retrospectively analyzed from 69 patients who underwent alIo-HSCT.All patients were divided into three groups according to the relation between donor and recipient and HLA matching:22 patients of sibling- matched bone marrow transplantation in group A;37 patients of sibling-matched peripheral blood stem cell transplantation in group B;10 patients of matched unrelated donor HSCT or sibling-mismatched HSCT in group C.All of them were subjected to chemotherapy for preconditioning before transplanta- tion,and short-term methoterexate(MTX)combined with cyclosporine(CsA)for GVHD prophylaxis after transplantation.Patients with limited cGVHD were usually treated with immunosuppressive agent(CsA or glucocorticoid)alone,and those with advanced condition were administrated with stan- dard regimen(CsA combined with glucocorticoid);while those with extensive cGVHD were treated with standard regimen(first line therapy).Those who were not responsive to first line therapy and had a progressive disease condition,or those who were refractory to the first line therapy and relapsed when drug withdrawal were treated with tacrolimus,mycophenolate and azathioprine(second line therapy).Results During a median follow-up period of 43 months(6-120 months),39 patients deve- loped cGVHD after transplantation.Limited cGVHD developed in 13 of 39 patients(33.3%),while extensive cGVHD developed in 26 of 39 patients(66.7%).Seven died of cGVHD or related compli- cations,cGVHD incidence in group B was much higher than in group A(P0.05),while incidence of extensive cGVHD in groups B and C were much higher than in group A(P0,05).Peripheral blood stem cell transplant and development of gradeⅡ-Ⅳacute GVHD were the independent risk factors of cGVHD.It was also proven that patients with limited eGVHD who treated with first line therapy had a better therapeutic effect than those with extensive cGVHD(P0.05);therapeutic effectiveness of first line therapy for cGVHD in standard risk group was much better than that in high risk group(P0.05).Conclusion cGVHD is the common complication and reasons of causing death in later period after allo-HSCT.Clinically extensive cGVHD usually develops in patients undergoing allo-PBSCT, HLA mismatched HSCT and MUD-HSCT,and has a worse clinical therapeutic effect.

[Clinical Characteristics of Acute Graft-Versus-host Disease Confined Solely to Gastrointestinal Tract after Allogeneic Hematopoietic Stem Cell Transplantation].

[Clinical Study of Intestinal Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Children].

[Exploration of Acute Graft Versus Host Disease and Its Risk Factors after Allo-Hematopoietic Stem Cell Transplantation].

[Analysis of Risk Factors for the Development of Acute Graft-Versus-host Disease in 151 Cases of Allo-Hematopoietic Stem Cell Transplantation].

A clinical study for acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation

Clinical characteristics of acute graft-versus-host disease among different donors of allogeneic hematopoietic stem cell transplantation.

[Effect of Graft-Versus-host Disease on Relapse and Survival in 100 Patients after Allogeneic Hematopoietic Stem Cell Transplantation].

Intestinal graft-versus-host disease after allogeneic hemapoietic stem cell transplantation

Clinical analysis of 24 patients with intestinal graf-versus-host disease after allogeneic hemapoietic stem cell transplantation

Clinical Study of Chronic Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Risk Factors for Acute Graft-Versus-Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Center Experience.

Risk Factors and Therapeutic Outcome of Intestinal Acute Graft Versus Host Disease in Acute Leukemia Patients after Haploidentical Peripheral Hematopoietic Stem Cell Transplantation

A Comparison of Clinical Characteristics and Prognosis of Adult Acute Graft-Versus-host Disease Between Human Leukocyte Antigen-Identical And-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

[Clinical Study on A Patient with Intestinal Acute Graft-Versus-Host Disease Grade IV after Allo-Peripheral Blood Stem Cell Transplantation]

Clinical Analysis on Graft-Versus-host Disease in 55 Cases of Allogeneic Hematopoietic Stem Cell Transplantation

Association Between CD34+ and CD3+ T-cells in Allogeneic Grafts and Acute Graft-Versus-host Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Study.

Interplay Between the Intestinal Microbiota and Acute Graft-Versus-Host Disease: Experimental Evidence and Clinical Significance

[Influence of Graft-Versus-host Disease on Long-Term Survival of 26 Patients with Hematologic Malignancies after Transplantation].

Features of gastrointestinal acute graft‐versus‐host disease in children undergoing hematopoietic stem cell transplantation

Prevalence of oral chronic graft versus host disease after allogeneic stem cell transplantation

Risk Factors for Chronic Graft-Versus-host Disease after Anti-Thymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia